A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolamide, interferon alfa, and interleukin-2 for metastatic melanoma.

被引：0
|
作者：
Ron, IG [1 ]
Ryvo, L [1 ]
Sarid, D [1 ]
Asna, N [1 ]
Inbar, MJ [1 ]
机构：
[1] Tel Aviv Med Ctr & Sch Med, IL-64239 Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7567
引用
收藏
页码：726S / 726S
页数：1
相关论文
共 50 条
  • [1] Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
    Legha, SS
    Ring, S
    Eton, O
    Bedikian, A
    Buzaid, AC
    Plager, C
    Papadopoulos, N
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1752 - 1759
  • [2] A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study
    Ron, IG
    Sarid, D
    Ryvo, L
    Sapir, EE
    Schneebaum, S
    Metser, U
    Asna, N
    Inbar, MJ
    Safra, T
    MELANOMA RESEARCH, 2006, 16 (01) : 65 - 69
  • [3] Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-α in patients with metastatic melanoma
    Cao, MG
    Malvehy, J
    Martí, R
    Conill, C
    Sánchez, M
    Martín, M
    Carrera, C
    Herrero, J
    Gascón, P
    Mellado, B
    Castel, T
    Puig, S
    MELANOMA RESEARCH, 2006, 16 (01) : 59 - 64
  • [4] A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon, and digoxin in melanoma patients
    Khan, M. I.
    Laber, D. A.
    Chesney, J.
    Taft, B.
    Miller, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon, and digoxin in melanoma matients
    Khan, M. I.
    Taft, B.
    Rasku, M. A.
    Laber, D.
    Chesney, J.
    Miller, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] ACUTE RHABDOMYOLYSIS AFTER CONCURRENT ADMINISTRATION OF INTERLEUKIN-2, INTERFERON-ALFA, AND CHEMOTHERAPY FOR METASTATIC MELANOMA
    ANDERLINI, P
    BUZAID, AC
    LEGHA, SS
    CANCER, 1995, 76 (04) : 678 - 679
  • [7] A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma
    McDermott, DF
    Mier, JW
    Lawrence, DP
    van den Brink, MRM
    Clancy, MA
    Rubin, KM
    Atkins, MB
    CLINICAL CANCER RESEARCH, 2000, 6 (06) : 2201 - 2208
  • [8] SEQUENTIAL CHEMOIMMUNOTHERAPY WITH CISPLATIN, INTERLEUKIN-2, AND INTERFERON ALFA-2A FOR METASTATIC MELANOMA
    KHAYAT, D
    BOREL, C
    TOURANI, JM
    BENHAMMOUDA, A
    ANTOINE, E
    RIXE, O
    VUILLEMIN, E
    BAZEX, PA
    THILL, L
    FRANKS, R
    AUCLERC, G
    SOUBRANE, C
    BANZET, P
    WEIL, M
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) : 2173 - 2180
  • [9] Cisplatin, interleukin-2, interferon-α and tamoxifen in metastatic melanoma.: A phase II study
    Naglieri, E
    Procacci, A
    Galetta, D
    Abbate, I
    Dell'Erba, L
    Colucci, G
    JOURNAL OF CHEMOTHERAPY, 1999, 11 (02) : 150 - 155
  • [10] Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
    Atkins, Michael B.
    Hsu, Jessie
    Lee, Sandra
    Cohen, Gary I.
    Flaherty, Lawrence E.
    Sosman, Jeffrey A.
    Sondak, Vernon K.
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5748 - 5754
12345